CytoDyn Inc (NASDAQ:CYDY) released its quarterly earnings data on Tuesday, October 10th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.03), Bloomberg Earnings reports.
CytoDyn (NASDAQ:CYDY) traded down 4.62% during trading on Friday, reaching $0.62. 20,650 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $0.65 and its 200-day moving average price is $0.65. The stock’s market cap is $96.78 million. CytoDyn has a one year low of $0.46 and a one year high of $0.84.
A number of analysts have recently weighed in on CYDY shares. Zacks Investment Research upgraded shares of CytoDyn from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. ValuEngine upgraded shares of CytoDyn from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. Finally, HC Wainwright set a $2.00 price target on shares of CytoDyn and gave the company a “buy” rating in a research report on Thursday, August 10th.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://weekherald.com/2017/10/20/cytodyn-inc-cydy-releases-quarterly-earnings-results-misses-estimates-by-0-03-eps.html.
CytoDyn Company Profile
CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.
Receive News & Ratings for CytoDyn Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc and related companies with MarketBeat.com's FREE daily email newsletter.